INVESTMENT HIGHLIGHTS
Why Upstream?

Opportunity

  • Diseases targeted have large market sizes & the need for new drugs

High Profit Ration Business Model

  • Easily expandable pipeline using Upstream’s proprietary low risk/low cost drug development program
  • Artificial intelligence based process effectively generates & screens potential drug candidates quickly and cheaply
  • Accelerated drug discovery process will lead to achieving milestones faster

Priority Review Vouchers

  • To offer incentives for tropical disease research, the FDA will accelerate drug application review by seven months AND provide the researching company a tradable voucher for similar priority review for a second non-tropical disease drug
  • This provides an estimated benefit to a Big Pharma of between $1.5 billion to $5 billion over the lifetime of the drug and sets a floor value of a drug at $300 million (NPV) and effectively gives Upstream a US market for our drug research.